AIM: To evaluate the usefulness of combined PET/CT examinations for detection of malignant tumors and their metastases in head and neck oncology. METHODS: 51 patients received whole body scans on a dual modality PET/CT system. CT was performed without i.v. contrast. The results were compared concerning the diagnostic impact of native CT scan on FDG-PET images and the additional value of fused imaging. RESULTS: From 153 lesions were 97 classified as malignant on CT and 136 on FDG/PET images, as suspicious for malignancy in 33 on CT and 7 on FDG-PET and as benign in 23 on CT and 10 on FDG-PET. With combined PET/CT all primary and recurrent tumors could be found, the detection rate in patients with unknown primary tumors was 45%. Compared to PET or CT alone the sensitivity, specifity and accuracy could be significantly improved by means of combined PET/CT. CONCLUSION: Fused PET/CT imaging with [F18]-FDG and native CT-scanning enables accurate diagnosis in 93% of lesions and 90% of patients with head and neck oncology.
AIM: To evaluate the usefulness of combined PET/CT examinations for detection of malignant tumors and their metastases in head and neck oncology. METHODS: 51 patients received whole body scans on a dual modality PET/CT system. CT was performed without i.v. contrast. The results were compared concerning the diagnostic impact of native CT scan on FDG-PET images and the additional value of fused imaging. RESULTS: From 153 lesions were 97 classified as malignant on CT and 136 on FDG/PET images, as suspicious for malignancy in 33 on CT and 7 on FDG-PET and as benign in 23 on CT and 10 on FDG-PET. With combined PET/CT all primary and recurrent tumors could be found, the detection rate in patients with unknown primary tumors was 45%. Compared to PET or CT alone the sensitivity, specifity and accuracy could be significantly improved by means of combined PET/CT. CONCLUSION: Fused PET/CT imaging with [F18]-FDG and native CT-scanning enables accurate diagnosis in 93% of lesions and 90% of patients with head and neck oncology.
Authors: Andreas Bockisch; Thomas Beyer; Gerald Antoch; Lutz S Freudenberg; Hilmar Kühl; Jörg F Debatin; Stefan P Müller Journal: Mol Imaging Biol Date: 2004 Jul-Aug Impact factor: 3.488
Authors: Panagiota Mantaka; Richard P Baum; Andreas Hertel; Stefan Adams; Andreas Niessen; Sonali Sengupta; Gustav Hör Journal: Cancer Biother Radiopharm Date: 2003-02 Impact factor: 3.099
Authors: E Kresnik; P Mikosch; H Gallowitsch; D Kogler; S Wieser; M Heinisch; O Unterweger; W Raunik; G Kumnig; I Gomez; G Grünbacher; P Lind Journal: Eur J Nucl Med Date: 2001-07
Authors: P Bruschini; A Giorgetti; L Bruschini; A Nacci; D Volterrani; M Cosottini; F Ursino; G Mariani; B Fattori Journal: Acta Otorhinolaryngol Ital Date: 2003-12 Impact factor: 2.124
Authors: Thomas Beyer; Gerald Antoch; Stefan Müller; Thomas Egelhof; Lutz S Freudenberg; Jörg Debatin; Andreas Bockisch Journal: J Nucl Med Date: 2004-01 Impact factor: 10.057